Top

BMC Cancer

Published in:

Open Access 01-12-2016 | Research article

Determining intrafractional prostate motion using four dimensional ultrasound system

Authors: Mariwan Baker, Claus F. Behrens

Published in: BMC Cancer | Issue 1/2016

Abstract

Background

In prostate radiotherapy, it is essential that the prostate position is within the planned volume during the treatment delivery. The aim of this study is to investigate whether intrafractional motion of the prostate is of clinical consequence, using a novel 4D autoscan ultrasound probe.

Methods

Ten prostate patients were ultrasound (US) scanned at the time of CT imaging and once a week during their course of radiotherapy treatment in an ethics-approved study, using the transperineal Clarity autoscan system (Clarity®, Elekta Inc., Stockholm, Sweden). At each US scanning session (fraction) the prostate was monitored for 2 to 2.5 min, a typical beam-on time to deliver a RapidArc® radiotherapy fraction. The patients were instructed to remain motionless in supine position throughout the US scans. They were also requested to comply with a bladder-filling protocol. In total, 51 monitoring curves were acquired. Data of the prostate motion in three orthogonal directions were analyzed. Finally, the BMI value was calculated to investigate correlation between BMI and the extent of prostate displacement.

Results

The patients were cooperative, despite extra time for applying the TPUS scan. The mean (±1SD) of the maximal intrafractional displacements were [mm]; I(+)/S: (0.2 ± 0.9); L(+)/R: (−0.2 ± 0.8); and A(+)/P: (−0.2 ± 1.1), respectively. The largest displacement was 2.8 mm in the posterior direction. The percentage of fractions with displacements larger than 2.0 mm was 4 %, 2 %, and 10 % in the IS, LR, and AP directions, respectively. The mean of the maximal intrafractional Euclidean distance (3D vector) was 0.9 ± 0.6 mm. For 12 % of the fractions the maximal 3D vector displacements were larger than 2.0 mm. At only two fractions (4 %) displacements larger than 3.0 mm were observed. There was no correlation between BMI and the extent of the prostate displacement.

Conclusions

The prostate intrafractional displacement is of no clinically consequence for treatment times in the order of 2 – 2.5 min, which is typical for a RapidArc radiotherapy fraction. However, prostate motion should be considered for longer treatment times eg if applying conventional or IMRT radiotherapy.

Scarbrough TJ, Golden NM, Ting JY, Fuller CD, Wong A, Kupelian P a, et al. Comparison of ultrasound and implanted seed marker prostate localization methods: Implications for image-guided radiotherapy. Int J Radiat Oncol Biol Phys [Internet]. 2006 Jun 1 [cited 2012 Nov 27];65(2):378–87. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16563658.

Kupelian PA, Langen KM, Willoughby TR, Zeidan OA, Meeks SL. Image-Guided Radiotherapy for Localized Prostate Cancer: Treating a Moving Target. Semin Radiat Oncol. 2008;18(1):58–66.CrossRefPubMed

Kitamura K. Three-dimensional intrafractional movement of prostate measured during real-time tumor-tracking radiotherapy in supine and prone treatment positions. Int J Radiat Oncol Biol Phys. 2002;53(5):1117–23.CrossRefPubMed

Li HS, Chetty IJ, Enke CA, Foster RD, Willoughby TR, Kupellian PA, et al. Dosimetric consequences of intrafraction prostate motion. Int J Radiat Oncol Biol Phys [Internet]. 2008 Jul 1 [cited 2015 Sep 2];71(3):801–12. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18234439.

Dawson LA. A comparison of ventilatory prostate movement in four treatment positions. Int J Radiat Oncol Biol Phys. 2000;48(2).

Padhani A. Evaluating the effect of rectal distension and rectal movement on prostate gland position using cine MRI. Int J Radiat Oncol Biol Phys. 1999;44(3):525–33.CrossRefPubMed

van Herk M. Quantification of organ motion during conformal radiotherapy of the prostate by three dimensional image registration. Int J Radiat Oncol Biol Phys. 1995;33(5):1311–20.CrossRefPubMed

Tong X, Chen X, Li J, Xu Q, Lin M, Chen L, et al. Intrafractional prostate motion during external beam radiotherapy monitored by a real-time target localization system. J Appl Clin Med Phys. 2015;16(2):51–61.

Mayyas E, Chetty IJ, Chetvertkov M, Wen N, Neicu T, Nurushev T, et al. Evaluation of multiple image-based modalities for image-guided radiation therapy (IGRT) of prostate carcinoma: a prospective study. Med Phys [Internet]. 2013;40(4):041707. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23556877.

10.

Chan P, Dinniwell R, Haider M a, Cho Y-B, Jaffray D, Lockwood G, et al. Inter- and intrafractional tumor and organ movement in patients with cervical cancer undergoing radiotherapy: a cinematic-MRI point-of-interest study. Int J Radiat Oncol Biol Phys [Internet]. 2008 Apr 1 [cited 2013 Dec 30];70(5):1507–15. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18164850.

11.

Ghilezan MJ, Jaffray D a, Siewerdsen JH, Van Herk M, Shetty A, Sharpe MB, et al. Prostate gland motion assessed with cine-magnetic resonance imaging (cine-MRI). Int J Radiat Oncol Biol Phys [Internet]. 2005 Jun 1 [cited 2012 Nov 1];62(2):406–17. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15890582.

12.

Kron T, Thomas J, Fox C, Thompson A, Owen R, Herschtal A, et al. Intra-fraction prostate displacement in radiotherapy estimated from pre- and post-treatment imaging of patients with implanted fiducial markers. Radiother Oncol [Internet]. 2010 May [cited 2015 Sep 2];95(2):191–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20189667.

13.

Adamson J, Wu Q. Inferences about prostate intrafraction motion from pre- and posttreatment volumetric imaging. Int J Radiat Oncol Biol Phys [Internet]. 2009 Sep 1 [cited 2015 Sep 2];75(1):260–7. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2730426&tool=pmcentrez&rendertype=abstract.

14.

Lachaine M, Falco T. Intrafractional prostate motion management with the Clarity Autoscan system. Med Phys Int [Internet]. 2013;1(1):72–80. Available from: http://federation-fampo.org/web/uploads/MPI-2013-01.pdf#page=72.

15.

Bittner N, Butler WM, Reed JL, Murray BC, Kurko BS, Wallner KE, et al. Electromagnetic tracking of intrafraction prostate displacement in patients externally immobilized in the prone position. Int J Radiat Oncol Biol Phys [Internet]. 2010 Jun 1 [cited 2015 Sep 2];77(2):490–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19775826.

16.

Wilbert J, Baier K, Hermann C, Flentje M, Guckenberger M. Accuracy of real-time couch tracking during 3-dimensional conformal radiation therapy, intensity modulated radiation therapy, and volumetric modulated arc therapy for prostate cancer. Int J Radiat Oncol Biol Phys [Internet]. 2013 Jan 1 [cited 2015 Sep 2];85(1):237–42. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22541958.

17.

Curtis W, Khan M, Magnelli A, Stephans K, Tendulkar R, Xia P. Relationship of imaging frequency and planning margin to account for intrafraction prostate motion: analysis based on real-time monitoring data. Int J Radiat Oncol Biol Phys [Internet]. 2013 Mar 1 [cited 2015 Sep 2];85(3):700–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22795802.

18.

Langen KM, Willoughby TR, Meeks SL, Santhanam A, Cunningham A, Levine L, et al. Observations on real-time prostate gland motion using electromagnetic tracking. Int J Radiat Oncol Biol Phys [Internet]. 2008 Jul 15 [cited 2015 Sep 2];71(4):1084–90. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18280057.

19.

Li JS. Observations of prostate intrafractional motion during external beam radiation therapy. Ifmbe Proc. 2009;25(1):499–502.CrossRef

20.

Ballhausen H, Li M, Hegemann N-S, Ganswindt U, Belka C. Intra-fraction motion of the prostate is a random walk. Phys Med Biol [Internet]. 2015;60(2):549–63. Available from: http://stacks.iop.org/0031-9155/60/i=2/a=549?key=crossref.1d37a7c57f0aac3a6191cff1152ecde0.CrossRef

21.

Li JS, Lin M-H, Buyyounouski MK, Horwitz EM, Ma C-M. Reduction of prostate intrafractional motion from shortening the treatment time. Phys Med Biol [Internet]. 2013 Jul 21 [cited 2015 Sep 2];58(14):4921–32. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3940444&tool=pmcentrez&rendertype=abstract.

22.

Mutanga TF, de Boer HCJ, Rajan V, Dirkx MLP, Incrocci L, Heijmen BJM. Day-to-day reproducibility of prostate intrafraction motion assessed by multiple kV and MV imaging of implanted markers during treatment. Int J Radiat Oncol Biol Phys [Internet]. 2012 May 1 [cited 2015 Sep 2];83(1):400–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22019244.

23.

van der Meer S, Bloemen-van Gurp E, Hermans J, Voncken R, Heuvelmans D, Gubbels C, et al. Critical assessment of intramodality 3D ultrasound imaging for prostate IGRT compared to fiducial markers. Med Phys. 2013;40(7):071707. Available from: http://scitation.aip.org/content/aapm/journal/medphys/40/7/10.1118/1.4808359/, http://www.ncbi.nlm.nih.gov/pubmed/23822411.

24.

Deegan T, Owen R, Holt T, Roberts L, Biggs J, McCarthy A, et al. Interobserver variability of radiation therapists aligning to fiducial markers for prostate radiation therapy. J Med Imaging Radiat Oncol [Internet]. 2013 Aug [cited 2015 Sep 2];57(4):519–23; quiz 524–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23870354.

25.

Kotte ANTJ. Intrafraction motion of the prostate during external-beam radiation therapy: analysis of 427 patients with implanted fiducial markers. Int J Radiat Oncol Biol Phys. 2007;69(2).

26.

Baker M, Behrens CF. Prostate displacement during transabdominal ultrasound image-guided radiotherapy assessed by real-time four-dimensional transperineal monitoring. Acta Oncol [Internet]. 2015 Oct [cited 2016 Jan 14];54(9):1508–14. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26203927.

27.

Abramowitz MC, Bossart E, Flook R, Wu X, Brooks R, Lachaine M, et al. Noninvasive Real-time Prostate Tracking Using a Transperineal Ultrasound Approach. Int J Radiat Oncol [Internet]. 2012 Nov [cited 2015 May 10];84(3):S133. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0360301612010899.

28.

Choi Y, Kwak D-W, Lee H-S, Hur W-J, Cho W-Y, Sung GT, et al. Effect of rectal enema on intrafraction prostate movement during image-guided radiotherapy. J Med Imaging Radiat Oncol [Internet]. 2015;59(2):236–42. Available from: http://doi.wiley.com/10.1111/1754-9485.12239.CrossRef

29.

Vargas C, Saito AI, Hsi WC, Indelicato D, Falchook A, Zengm Q, et al. Cine-magnetic resonance imaging assessment of intrafraction motion for prostate cancer patients supine or prone with and without a rectal balloon. Am J Clin Oncol [Internet]. 2010 Feb [cited 2015 Sep 7];33(1):11–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19730351.

30.

Smeenk RJ, Louwe RJW, Langen KM, Shah AP, Kupelian PA, van Lin ENJT, et al. An endorectal balloon reduces intrafraction prostate motion during radiotherapy. Int J Radiat Oncol Biol Phys [Internet]. 2012 Jun 1 [cited 2015 Aug 17];83(2):661–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22099035.

31.

Shelton J, Rossi PJ, Chen H, Liu Y, Master V a., Jani AB. Observations on prostate intrafraction motion and the effect of reduced treatment time using volumetric modulated arc therapy. Pract Radiat Oncol [Internet]. American Society for Radiation Oncology; 2011;1(4):243–50. Available from: http://dx.doi.org/10.1016/j.prro.2011.02.008.

32.

Ng JA, Booth JT, Poulsen PR, Fledelius W, Worm ES, Eade T, et al. Kilovoltage intrafraction monitoring for prostate intensity modulated arc therapy: first clinical results. Int J Radiat Oncol Biol Phys [Internet]. 2012 Dec 1 [cited 2015 Sep 8];84(5):e655–61. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22975613.

33.

Lometti M. Intra-fraction prostate motion using MV fluoroscopy. Int J Radiat Oncol Biol Phys. 2005;63(2).

34.

Wang KK, Vapiwala N, Deville C, et al. A study to quantify the effectiveness of daily endorectal balloon for prostate intrafraction motion management. Int J Radiat Oncol Biol Phys. 2012;83:1055–63. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22115790.CrossRefPubMed

Title: Determining intrafractional prostate motion using four dimensional ultrasound system
Authors: Mariwan Baker
Claus F. Behrens
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2016
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-016-2533-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2016

Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement

Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer

Expression of F-actin-capping protein subunit beta, CAPZB, is associated with cell growth and motility in epithelioid sarcoma

Cervical and breast cancer screening participation for women with chronic conditions in France: results from a national health survey

Lifestyle in Multiple Myeloma - a longitudinal cohort study protocol

Spinal disease in myeloma: cohort analysis at a specialist spinal surgery centre indicates benefit of early surgical augmentation or bracing

Keynote webinar | Spotlight on antibody–drug conjugates in cancer